2 completed, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Unknown 1, Withdrawn 1 |
Follow hetrombopag: new trials by email Literature Review of hetrombopag trials Research Report on hetrombopag
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study Hetrombopag, Placebo - Thrombocytopenia, Hepatic Interventional Procedure | Phase 3 | Not yet recruiting | Zhongda Hospital | 108 | 2026-10-15 | 2026-11-09 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. Hetrombopag, Hetrombopag plus Placebo, Placebo - Chemotherapy-Induced Thrombocytopenia | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 213 | 2023-04-25 | 2025-04-16 |
| A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia Hetrombopag, Matching placebo - Chemotherapy-Induced Thrombocytopenia | Phase 3 | Withdrawn | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-15 | 2023-09-28 | |
| Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia Hetrombopag, Stanozolol Tablets - MDS | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 50 | 2021-10-01 | 2021-09-24 |
| Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Hetrombopag - Aplastic Anemia, Drug Effect | Phase 2 / Phase 3 | Withdrawn | Peking Union Medical College Hospital | 2021-10-01 | 2026-06-08 | |
| Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia Hetrombopag, Placebo - Immune Thrombocytopenia | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2021-03-29 | 2025-07-18 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. Hetrombopag, Placebo - Chemotherapy-Induced Thrombocytopenia | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 129 | 2019-11-06 | 2025-05-16 |
Anemia, Aplastic (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Thrombocytopenia (1)
Jiangsu HengRui Medicine Co., Ltd. (4) · Peking Union Medical College Hospital (2) · Zhongda Hospital (1)
China (5)
Bing Han, Docter (1) · Bing Han, Master (1) · Gao-jun Teng (1)